AVTX Cuts Losses but Revenue Plummets 69%

Avalo Therapeutics (AVTX) reported fiscal 2025 Q4 results on March 23, 2026, with a 61.2% reduction in net losses year-over-year, though revenue plummeted 69.3%. The company’s GAAP EPS of -$5.84 beat estimates by $0.47, while cash reserves of $98 million are projected to fund operations through 2028, aligning with disciplined cost management.

Revenue

The total revenue of Avalo Therapeutics decreased by 69.3% to $59,000 in 2025 Q4, down from $192,000 in 2024 Q4.

Earnings/Net Income

Avalo Therapeutics narrowed losses to $0.74 per share in 2025 Q4 from a loss of $3.37 per share in 2024 Q4 (78.0% improvement). Meanwhile, the company successfully narrowed its net loss to $-13.72 million in 2025 Q4, reducing losses by 61.2% compared to the $-35.34 million net loss reported in 2024 Q4. The EPS improvement signals progress, though sustained losses underscore financial challenges.

Price Action

The stock price of Avalo Therapeutics has edged up 0.60% during the latest trading day, has plummeted 15.73% during the most recent full trading week, and has plummeted 15.47% month-to-date.

Post-Earnings Price Action Review

The strategy of buying Avalo Therapeutics (AVTX) shares after a revenue drop quarter-over-quarter on the financial report release date and holding for 30 days resulted in a significant loss. The strategy had a return of -99.69%, underperforming the benchmark by 144.01%. With a maximum drawdown of 99.93% and a Sharpe ratio of -0.49, the strategy indicated a high risk and substantial volatility, highlighting the importance of risk management in such a volatile scenario.

CEO Commentary

Dr. Garry Neil, Chief Executive Officer, highlighted 2025 as a year of disciplined execution focused on advancing the Phase 2 LOTUS trial of abdakibart (AVTX-009) for hidradenitis suppurativa. He emphasized the anticipated release of topline data in Q2 2026 as a transformational milestone, expressing optimism about the drug’s potential to address unmet patient needs through high-affinity IL-1β inhibition. The commentary underscored strategic prioritization of clinical development, with operational efficiency and cash runway sustainability into 2028, reflecting a cautiously optimistic outlook.

Guidance

The company expects topline data from the Phase 2 LOTUS trial in Q2 2026, with cash, cash equivalents, and short-term investments of ~$98 million projected to fund operations through 2028. Forward-looking statements include R&D expenses of $50.1 million in 2025 and G&A expenses of $22.9 million, driven by trial-related costs and headcount. The guidance aligns with disciplined cash management and operational execution, with no explicit revenue or EPS forecasts provided.

Additional News

Avalo Therapeutics disclosed a 2025 net loss of $78.3 million, with Q4 adjusted loss per share at -$1.13 and zero revenue reported. The company’s stock fell 26.1% in the quarter, while analysts’ median 12-month target of $36 contrasts with its closing price of $13.42. No dividend activity was reported in the three weeks preceding the earnings release, and the firm remains focused on clinical milestones rather than shareholder returns.